Shaanxi Meibang Pharmaceutical Group Co., Ltd. (605033.SS)
CNY 12.67
(-0.63%)
CNY 12.67
(-0.63%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 353.69 Million CNY | -22.65% |
| 2022 | 457.28 Million CNY | -18.28% |
| 2021 | 559.55 Million CNY | 101.3% |
| 2020 | 277.96 Million CNY | 17.75% |
| 2019 | 236.06 Million CNY | -19.84% |
| 2018 | 294.48 Million CNY | 34.53% |
| 2017 | 218.9 Million CNY | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 180.54 Million CNY | -26.2% |
| 2024 Q3 | 175.55 Million CNY | -2.76% |
| 2024 Q1 | 244.63 Million CNY | -30.84% |
| 2023 Q4 | 353.69 Million CNY | 17.2% |
| 2023 FY | 353.69 Million CNY | -22.65% |
| 2023 Q3 | 301.78 Million CNY | 1.94% |
| 2023 Q2 | 296.05 Million CNY | -10.82% |
| 2023 Q1 | 331.95 Million CNY | -27.41% |
| 2022 Q3 | 524.44 Million CNY | 46.35% |
| 2022 Q2 | 358.33 Million CNY | -5.29% |
| 2022 Q1 | 378.34 Million CNY | -32.39% |
| 2022 FY | 457.28 Million CNY | -18.28% |
| 2022 Q4 | 457.28 Million CNY | -12.8% |
| 2021 Q4 | 559.55 Million CNY | 40.21% |
| 2021 Q3 | 399.08 Million CNY | 92.15% |
| 2021 Q2 | 207.69 Million CNY | -20.95% |
| 2021 FY | 559.55 Million CNY | 101.3% |
| 2021 Q1 | 262.72 Million CNY | -5.48% |
| 2020 FY | 277.96 Million CNY | 17.75% |
| 2020 Q1 | - CNY | 0.0% |
| 2020 Q4 | 277.96 Million CNY | 0.0% |
| 2020 Q2 | 150.86 Million CNY | 0.0% |
| 2019 FY | 236.06 Million CNY | -19.84% |
| 2018 FY | 294.48 Million CNY | 34.53% |
| 2017 FY | 218.9 Million CNY | 0.0% |